Lyme disease in North America is caused by the spirochete Borrelia burgdorferi (4, 38) . B. burgdorferi has an unusual eubacterial genome composed of mostly linear DNA molecules (2, 3, 5, 10, 15, 18, 35, 36 ) with a few circular DNA molecules (2, 21, 33, 36) . We have recently shown that B. burgdorferi is highly susceptible to growth inhibition by coumarin antimicrobial agents (33) , which inhibit the enzyme DNA gyrase (13, 17, 24, 28, 42) . Furthermore, the circular DNA molecules of B. burgdorferi are relaxed by coumermycin A1 treatment (33) .
DNA gyrase is a prokaryotic type II DNA topoisomerase, which introduces negative supercoiling into DNA by transiently nicking both strands of the helix and using ATP hydrolysis to pass another portion of the DNA molecule through the double-stranded break (9, 12, 16, 28) . The enzyme, which is required for cell growth and replication, is a tetramer composed of two A subunits and two B subunits. The A subunit interacts with DNA and is responsible for the breaking-rejoining reaction, while the B subunit contains the ATPase activity. Coumarin drugs, such as coumermycin A1, bind to the B subunit of DNA gyrase and inhibit its ATPase activity (17, 25, 37, 39) , most likely by a noncompetitive mechanism that involves stabilizing a protein conformation with a low affinity for ATP (1, 24) .
Resistance to coumarin drugs has been mapped to gyrB, the gene encoding DNA gyrase B (14, 17, 19, 27, 29) . Molecular studies have demonstrated that mutations in the N-terminal domain of DNA gyrase B, which contains the ATP-binding site (1, 41) , confer drug resistance (8, 11, 19, 40) . The most common mutations in Escherichia coli are those that change Arg-136 (in the N-terminal domain) of DNA gyrase B to Leu, Cys, His, or Ser (8, 11) . In addition, a mutation that changes Gly-164 to Val confers a temperature-sensitive resistance to the coumarin antibiotic chlorobiocin (8) . A mutant of the halophilic archaebacterium Haloferax sp. resistant to the coumarin antibiotic novobiocin had mutations at three residues, which correspond to Gly-81 (which is not a conserved residue), Ser-121, and Arg-136 in E. coli (19) . The mutation at the Arg residue is thought to be primarily responsible for the drug resistance (24) .
There are very few mutants of B. burgdorferi derived from selection (6, 7, 30, 31) Mutations in the gyrB gene correlated with coumermycin A1 resistance. DNA was isolated from wild-type and coumermycin A1-resistant B. burgdorferi as described previously (33) . The gyrase genes have been mapped to near the center of the linear chromosome (5, 26) . The region of the gyrB gene encoding a portion of the N-terminal domain was amplified by PCR, using a GeneAmp kit (Perkin-Elmer Cetus) with 292F (5'-GGTG GTAAGTITTAATAAAGGCACG) and 582R (5'-GTl7'A AAAAAGCAAGCTCT'ITAAG) as primers (20, 26) . We determined the sequence of the gyrB gene from nucleotides 316 to 558 (Fig. 1A) , using a dsDNA Cycle Sequencing System (Life Technologies/BRL). This N-terminal 81-amino-acid region shares 50% amino acid identity with the E. coli protein.
This conservation provides an unequivocal alignment of the gyrB gene products in which the B. burgdorferi Arg-133 corresponds to Arg-136 of E. coli (Fig. 1B) . This Arg residue was conserved in B. burgdorferi 212 (26), B31 (Fig. 1B) , JD-1, Sh-2-82, and CA-11.2A (data not shown). The B31 sequence was identical to the 212 sequence (GenBank accession number L14948) between nucleotides 316 and 558. CR8A, which is 100-fold more resistant than the wild type, was found to have an A-to-G transition (Fig. IA) that resulted in an Arg-133-toGly change. All nine members of the CR1OE group, which are 300-fold more resistant than the wild type, were found to have a G-to-T transversion (Fig. 1A) that converted Arg-133 to Ile. No other mutations were found in the region of gyrB that encodes amino acid residues 106 to 186 (which includes Ser-118 and Gly-161, corresponding to Ser-121 and Gly-164, respectively, in E. coli) in any of the coumermycin A,-resistant variants (Fig. 1A) . In addition, Southern blotting indicates that there is only one copy of the gyrB gene per chromosome in CR1OE (34 (24) . A corresponding Arg residue is found in all DNA gyrase B proteins whose sequence is known (Fig. 1B) except that from Streptomyces sphaeroides, which is the producer of the coumarin antibiotic novobiocin (40) . In E. coli, mutations of Arg-136 to His, Arg-136 to Ser or Cys, and Arg-136 to Leu confer 5-, -20-, and 64-fold resistance, respectively, to coumarin drugs (8, 11) , while the three mutations, including Arg-137 to His, confer -1,000-fold resistance to coumarin drugs in Haloferax sp. (19) . The mutation in B. burgdorferi that correlates with coumermycin A1 resistance is Arg-133 to Ile or Gly, neither of which has been previously described in any other bacteria. The level of resistance in these variants is 100-to 300-fold relative to the wild-type level. We did not identify any mutations of Arg-133 to Ser, which is possible with a single base change from the B. burgdorferi Arg codon (AGA). This may be because the Arg-133-to-Ser change does not confer enough resistance to allow for selection under our conditions (despite the low concentration of coumermycin A1 used). On the other hand, an Arg-136-to-Gly mutation has not been detected in E. coli in spite of extensive searches (24) . This may be due to differences between the DNA gyrase B proteins of the two bacteria: although they share 54% overall identity, they are significantly different in size. The crystal structure of the N-terminal domain of the B subunit in E. coli indicates that Arg-136 interacts with Tyr-5 (41) and may, therefore, have an indirect role in forming the ATP binding pocket (24) .
The coumermycin A,-resistant mutants grew slightly slower than the wild-type strain. This slower growth rate may be due to the decreased activity of the drug-resistant DNA gyrase, although some coumarin-resistant strains of E. coli grow at the same rate as wild-type strains (8 (32) , indicative of a mutant DNA gyrase (8) . We are currently using coumarin-resistant gyrB as a selectable marker for genetic studies in B. burgdorferi (34) .
